Company Overview and News

39
Closing Bell: Sensex ends 200 pts higher, Nifty closes above 10,600; PSU banks fall

2018-04-26 moneycontrol
3:30 pm Market at Close: Shares have ended the day on a strong note, with the Sensex rising over 200 points, while the Nifty is above 10,600-mark.The market breadth is negative as 1102 shares advanced against a decline of 1507 shares, while 177 shares were unchanged.
RMGALLOY 500408 500325 VISAKAIND 532832 534816 500134 500570 RLNIY UNIPLY AXB RELCAPITAL YYBKY STS AXBA ROHLTD 500180 534809 TCS PCJEWELLER IBREALEST RALLIS BHRYY 533150 RELIANCE NFL BHRQY TTNQY 532699 532215 SHAHALLOYS SPMWY EQMNY 532540 AXISBANK RIGD SUPREMEIND 500355 INFRATEL HDFCBANK BHARTIARTL TATAMOTORS 503100 523630 500111 YESBANK 517354 HVLQY PHOENIXLTD IBN ESSAROIL 532648 513436 532646 TAKE AXBKY 532454 ICICIBANK GODREJPROP 532890 HDB 532174 500365 HAVELLS TATAELXSI 509055 509930 TTM

Related Articles

HIMX: Himax Technologies Analysis and Research Report

2018-06-24 - Asif

History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...